11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Faculty Opinions recommendation of 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3102957.2785055 ◽

2010 ◽

Author(s):

Jean-Francois Demonet

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Amyloid Beta ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

The Lancet Neurology ◽

10.1016/s1474-4422(13)70014-0 ◽

2013 ◽

Vol 12 (3) ◽

pp. 233-243 ◽

Cited By ~ 122

Author(s):

Richard Dodel ◽

Axel Rominger ◽

Peter Bartenstein ◽

Frederik Barkhof ◽

Kaj Blennow ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Intravenous Immunoglobulin ◽

Dose Finding ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

P4-218: A phase I, double-blind, placebo-controlled, randomized, multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of PF 04447943 in mild-to-moderate Alzheimer's disease subjects on stable donepezil therapy

10.1016/j.jalz.2011.05.2241 ◽

2011 ◽

Vol 7 ◽

pp. S781-S781

Author(s):

Rebecca Evans ◽

Timothy Nicholas ◽

Vu Le ◽

William Martin ◽

David Martin ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase I ◽

Multiple Dose ◽

Double Blind ◽

Double Blind Placebo ◽

Multiple Dose Study ◽

The PIONEER Study: A multi‐center, randomized, double‐blind, placebo‐controlled phase 2 trial of the effects of T3D‐959 on safety, cognition, function and plasma biomarkers in mild to moderate Alzheimer’s disease subjects: Rationale and study design

10.1002/alz.039922 ◽

2020 ◽

Vol 16 (S9) ◽

Author(s):

John Didsbury ◽

Warren Strittmatter ◽

Stan Chamberlain ◽

Hoda Gabriel

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Study Design ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Plasma Biomarkers ◽

Phase 2 Trial ◽

Pioneer Study

INVOKE‐2: A phase 2 randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of AL002 in participants with early Alzheimer’s disease

10.1002/alz.054615 ◽

2021 ◽

Vol 17 (S9) ◽

Author(s):

Robert Paul ◽

Sam Jackson ◽

Michael Ward ◽

Aashka Joshi ◽

Abraham Castro ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Controlled Study ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Early Alzheimer’S Disease

P3-033: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS TREATMENT OF BIIB092 IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE: TANGO PHASE 2 STUDY DESIGN

10.1016/j.jalz.2018.06.1388 ◽

2006 ◽

Vol 14 (7S_Part_20) ◽

pp. P1077-P1077 ◽

Cited By ~ 1

Author(s):

Elena Ratti ◽

Bjoern Sperling ◽

Tina Olsson ◽

Li Zhang ◽

Kumar Kandadi Muralidharan ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Study Design ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Early Alzheimer’S Disease

P2-006: Exploratory Analyses of Cognitive Effects of Crenezumab in a Mild Alzheimer's Disease Subpopulation of a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Study (ABBY)

10.1016/j.jalz.2016.06.1210 ◽

2016 ◽

Vol 12 ◽

pp. P610-P610 ◽

Cited By ~ 2

Author(s):

Howard Mackey ◽

William Cho ◽

Michael Ward ◽

Yuan Fang ◽

Shehnaaz Suliman ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Effects ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group ◽

Phase 2 Study

P3-288: A randomized, double-blind, placebo-controlled, multiple ascending dose study of hdac inhibition for modulation of apoj/clusterin expression as a risk factor for Alzheimer's disease

10.1016/j.jalz.2015.06.1661 ◽

2015 ◽

Vol 11 (7S_Part_16) ◽

pp. P742-P743

Author(s):

Gregory A. Jicha ◽

Erin L. Abner ◽

Richard J. Kryscio ◽

Steve Estus

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Risk Factor ◽

Hdac Inhibition ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Study ◽

Clusterin Expression

O4-11-06: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

10.1016/j.jalz.2014.04.450 ◽

2014 ◽

Vol 10 ◽

pp. P275-P275 ◽

Cited By ~ 14

Author(s):

Jeffrey Cummings ◽

William Cho ◽

Michael Ward ◽

Michel Friesenhahn ◽

Flavia Brunstein ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study

P1-299: A phase i, randomized, double-blind, placebo-controlled, multiple ascending dose study of AT-001 yeast selenium for the prevention of Alzheimer's disease

10.1016/j.jalz.2015.06.500 ◽

2015 ◽

Vol 11 (7S_Part_10) ◽

pp. P471-P471 ◽

Cited By ~ 1

Author(s):

Gregory A. Jicha ◽

Erin L. Abner ◽

Richard J. Kryscio ◽

Casey Witt ◽

Alex Yiannikouris ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase I ◽

Double Blind ◽

Double Blind Placebo ◽